(in million U.S. dollars)
AbbVie
Inc. is a global, diversified research-based biopharmaceutical company
positioned for success with a comprehensive product portfolio that has
leadership positions across immunology, oncology, aesthetics, neuroscience and
eye care.
Immunology Portfolio: AbbVie maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology.
Revenue (2024):
AbbVie forecasts 2025
AbbVie is issuing its adjusted
diluted EPS guidance for the full-year 2025 of $12.12 to $12.32. The company's
2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D
and milestones that may be incurred during 2025, as both cannot be reliably
forecasted.
Long-Term
Outlook
AbbVie is reaffirming its
expectations for a high single-digit compound annual revenue growth rate
through 2029. This guidance assumes 2024 as the base year in the compound
annual growth rate calculation.
AbbVie is raising its long-term outlook for Skyrizi and Rinvoq revenues. The company now expects combined Skyrizi and Rinvoq 2027 revenues of more than $31 billion, an increase of approximately $4 billion compared to previous guidance for combined revenues of more than $27 billion in 2027. This guidance assumes Skyrizi revenues of more than $20 billion and Rinvoq revenues of more than $11 billion in 2027.
AbbVie is also updating its outlook for aesthetics revenues. The company now expects a high single-digit compound annual revenue growth rate for aesthetics through 2029. This guidance assumes 2025 as the base year in the compound annual growth rate calculation.
(in million U.S. dollars)
Johnson & Johnson and its
subsidiaries (the Company) is engaged in the
research and development, manufacture and sale of a broad range of products in
the healthcare field. Company is organized into two business segments:
Innovative Medicine and MedTech.
Immunology Portfolio (Innovative Medicine): Johnson & Johnson maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology
Revenue (2024):
2025 Phasing Considerations
(in million U.S. dollars)
Eli Lilly and Company (referred
to as the company, Lilly) a drug manufacturing company discovers, develops,
manufactures, and markets products in a single business segment—human
pharmaceutical products. Eli Lilly focuses on four core therapeutic areas— Cardiometabolic
Health products, Immunology, Neuroscience and Oncology.
Immunology Portfolio: Eli Lilly and Company maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology.
Revenue (2024):
2025 revenue guidance:
(in million Swiss Franc)
Roche
is one of the world’s largest biotech companies, as well as a leading provider
of in-vitro diagnostics and a global supplier of transformative innovative
solutions across major disease areas. A global pioneer in pharmaceuticals and
diagnostics. #1 in Neurology, a leader in Ophthalmology and
Oncology/Hematology. Roche focuses on five core therapeutic areas
(Pharmaceuticals Division) - Oncology/Haematology, Immunology, Neurology, Ophthalmology and
Cardiovascular/Renal/Metabolism.
Immunology Portfolio (Pharmaceuticals Division):
Revenue (2024):
(in million U.S. dollars)
Novartis is an innovative medicines company,
engaged in the research, development, manufacturing, distribution, marketing
and sale of a broad range of innovative pharmaceutical medicines. Novartis
focuses on four core therapeutic areas with strong growth potential and high
unmet patient needs—cardiovascular, renal and metabolic; immunology;
neuroscience; and oncology.
Immunology Portfolio (Innovative Medicine): Novartis maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology
Revenue (2024):
2025 Growth Plans: